New

Remepy

The AI engine Fit Assessment

Beta

Remepy develops pharma-tech solutions by integrating pharmaceuticals with AI-driven digital interventions, and partners with pharma companies to commercialize Hybrid Drugs.

Blurb

Remepy is biotechnology research pioneering hybrid drugs.

HQ Location

Ramat Gan (Israel)

Founded

2022

Employees

11 - 50

Total funding raised

$15.00M

Funding Status

Seed, $10.00M, May 1, 2024

Remepy is Pioneering Hybrid Drugs™.

Many medical conditions are better treated by combining pharmaceutical and non-pharmaceutical treatments. Hybrid drugs are a new type of drug asset, that combines traditional drugs with proprietary treatment protocols delivered measured and adapted using our AI capabilities.

Remepy’s Digital Molecules™ are designed to be the software apps within Hybrid Drugs™. They are based on digital interventions and treatment protocols that are tailored to each medical condition and its corresponding drug and are constantly measured and tracked and personalized using advanced AI capabilities.

The Digital Molecules™ enhance brain functions that balance the patient's neuro-endocrine and neuro-immunological systems and boost brain neuroplasticity, in order to optimize drug performance. We also address physical, motor, psychological, and behavioral symptoms



Remepy partners with pharma companies to bring Hybrid Drugs™ to market that will combine Remepy’s Digital Molecule™ and traditional drug components.